Although KRAS mutations are generally mutually exclusive with other oncogenic mutations, co-mutations in tumour suppressor genes such as STK11, TP53 or KEAP1 are frequently seen in KRAS-mutant tumours. This evidence concerns the gene STK11 and neoplasm.